Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmesis InternationalSGX:BFK 31 Median PS Value is S$0.10 as of Aug. 08, 2026, which is 100% below its 10-year median of 1.04. GuruFocus rates SGX:BFK with a GF Score™ of 31/100 and a GF Value™ of S$0.09 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 546 Drug Manufacturers companies, Pharmesis International ranks worse than 63.74% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Pharmesis International's Median PS Value or its related term are showing as below:
SGX:BFK'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5 Med: 1.04 Max: 3.8
Current: 1.07
During the past 13 years, the highest Price to Median PS Value of Pharmesis International was 3.80. The lowest was 0.50. And the median was 1.04.
SGX:BFK's Price-to-Median-PS-Value is ranked worse than 63.74% of 546
companies
in the Drug Manufacturers industry
Industry Median: 0.88
vs SGX:BFK: 1.07
Pharmesis International (SGX:BFK) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Pharmesis International's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.107
/
0.10
=
1.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International Median PS Value Related Terms
Pharmesis International Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:BFK vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmesis International Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Pharmesis International's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.4016.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was S$0.249.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International (SGX:BFK) has a Median PS Value of S$0.10 as of Aug. 08, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Pharmesis International and its competitors. This is 90% below median its historical median of 1.04. Over the past decade, Pharmesis International's Median PS Value has ranged from 0.50 to 3.80. According to the industry distribution chart, Pharmesis International ranks #348 out of 546 companies in the Drug Manufacturers industry, placing it in the top 63.7%.
Is Pharmesis International's Median PS Value too high?
Pharmesis International's current Median PS Value of S$0.10 is 90% below median its 10-year median of 1.04. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 3.80. Based on the distribution chart, Pharmesis International ranks #348 out of 546 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Pharmesis International ranks #348 out of 546 companies for Median PS Value. This places Pharmesis International in the lower half of its industry. The industry median Median PS Value is 0.88. Historically, Pharmesis International's own Median PS Value has ranged from 0.50 to 3.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.88, based on 546 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Pharmesis International and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmesis International's current Median PS Value is S$0.10, which is 90% below median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Median PS Value is S$0.10, which is 90% below median its 10-year median of 1.04. Pharmesis International's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Median PS Value is S$0.10 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued.
The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09.
GuruFocus considers Pharmesis International to be Modestly Overvalued.
Key valuation signals for SGX:BFK:
Median PS Value: S$0.10 (90% below median its 10-year median of 1.04)
GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score
Get the complete analysis for SGX:BFK
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
